ATP is an important
inflammatory and vasoactive mediator, which acts via two receptor classes;
P2X and P2Y. Activation of P2X receptors has traditionally been associated
with the well characterised vasoconstrictor properties of ATP. However,
we have recently demonstrated that the ATP - induced vasodilator response
in rat mesenteric vessels appears to be linked to the constrictor properties
of ATP (Ravelic, 2002; Harrington and Mitchell, 2003). Secondly we have
identified endothelium derived hyperpolarising factor (EDHF) as the main
mediator in ATP-induced dilator responses in mesenteric vessels (Harrington
and Mitchell 2003). In the current study, we have investigated the effects
of the highly specific P2X receptor ligand, Male Wistar rats (200 ± 15.4g) were killed by lethal exposure to CO2 followed by cervical dislocation. Second order mesenteric arteries were mounted in myographs and vasomotor responses recorded. Tissues were immersed in physiological salt solution (PSS), equilibrated (30 min) and tensions normalised as described previously (Mulvany and Halpern, 1977). Tissues were pre-contracted with methoxamine (10-5M). In some experiments the endothelium was removed mechanically. 10-4M
Traces of arteries with (+) or without (-) endothelial cells (EC). However, dilator responses were inhibited by high K+ or the combination of 100nM charybdotoxin plus 500nM apamin (C/A) and abolished by the combination of L-NAME, indomethacin, charybdotoxin, and apamin, figure 2; (T. Con. represents time control). Data is shown as the mean ± s.e.m. for n=3-8 experiments. Statistical significance was established using one-way ANOVA followed by Dunnetts Multiple Comparison Test. p<0.001; *p<0.05, ***p<0.001. These results show that P2X receptor activation results in endothelial cell dependent vasodilation mediated primarily via the release of EDHF. These observations have important implications for our understanding of the role of purines in biological responses.
Harrington LS and
Mitchell JA (2003) Br. J. Pharm. 140, 8P. This work was supported by the British Heart Foundation. |